Curis to Present at Upcoming Healthcare Conference in April

LEXINGTON, Mass., April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.

Read more at prnewswire.com